Brief: Isofol: Clinical Use Patent In Europe For Drug Candidate Arfolitixorin Will Be Approved
March 22 (Reuters) - Isofol Medical AB (publ) ISOFOL.ST :
* ISOFOL RECEIVES NOTICE THAT CLINICAL USE PATENT IN EUROPE
FOR
DRUG CANDIDATE ARFOLITIXORIN WILL BE APPROVED
* PATENT COVERS A DOSE REGIMEN FOR TREATING SOLID TUMORS,
SUCH AS
COLORECTAL, STOMACH, BREAST AND LIVER CANCER AND EXPIRES IN 2038
Source text for Eikon: ID:nWkr4fls4q
Further company coverage: ISOFOL.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 587696600;))
Recent news on Isofol Medical AB (publ)
See all newsSweden's Isofol Medical Q1 net loss widens, raises funds
Brief: Isofol Medical Q1 Net Income SEK -15.062 Million
Brief: Isofol Medical Announces Bfarm Approval Of Optimized Phase Ib/Ii Study Design
Brief: Isofol Gets Gross Proceeds Of SEK 18.9 Mln In Connection With Exercise Of Warrants And Guarantee Commitments
Brief: Isofol Secures License Rights For Arfolitixorin In Autism